Kunal Merchant

2.9k total citations · 1 hit paper
39 papers, 2.2k citations indexed

About

Kunal Merchant is a scholar working on Epidemiology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kunal Merchant has authored 39 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 10 papers in Hepatology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kunal Merchant's work include Liver Disease and Transplantation (9 papers), Inflammatory Bowel Disease (7 papers) and Microscopic Colitis (6 papers). Kunal Merchant is often cited by papers focused on Liver Disease and Transplantation (9 papers), Inflammatory Bowel Disease (7 papers) and Microscopic Colitis (6 papers). Kunal Merchant collaborates with scholars based in United States, United Kingdom and Germany. Kunal Merchant's co-authors include Jonathan S. Stamler, Harvey E. Marshall, William P. Forbes, Enoch Bortey, Shirley Huang, Fred Poordad, Arun J. Sanyal, Samuel H. Sigal, Audrey L. Shaw and Nathan M. Bass and has published in prestigious journals such as New England Journal of Medicine, Cell and Gastroenterology.

In The Last Decade

Kunal Merchant

39 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rifaximin Treatment in Hepatic Encephalopathy

2010 848 citations Nathan M. Bass, Kevin D. Mullen et al. New England Journal of Medicine profile →

Peers

Kunal Merchant

EPIDE

HEPAT

SURGE

PHYSI

J Giboudeau France

Hans‐Michael Steffen Germany

M Bilzer Germany

Yuji Ogawa Japan

Bruce F. Scharschmidt United States

Hitoshi Togashi Japan

Cheng Ji United States

Paul W. Hruz United States

Sujun Zheng China

H Harris United Kingdom

J Giboudeau France

Kunal Merchant

735 ×0.8

EPIDE

610 ×0.7

HEPAT

468 ×0.7

355 ×0.6

SURGE

409 ×1.2

PHYSI

Citations per year, relative to Kunal Merchant Kunal Merchant (= 1×) peers J Giboudeau

Countries citing papers authored by Kunal Merchant

Since Specialization

Citations

This map shows the geographic impact of Kunal Merchant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunal Merchant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunal Merchant more than expected).

Fields of papers citing papers by Kunal Merchant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kunal Merchant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunal Merchant. The network helps show where Kunal Merchant may publish in the future.

Co-authorship network of co-authors of Kunal Merchant

This figure shows the co-authorship network connecting the top 25 collaborators of Kunal Merchant. A scholar is included among the top collaborators of Kunal Merchant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kunal Merchant. Kunal Merchant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maurer, Marcus, Martin Metz, John Anderson, et al.. (2023). Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria. Journal of Allergy and Clinical Immunology. 151(2). AB133–AB133. 5 indexed citations

Terhorst‐Molawi, Dorothea, Tomasz Hawro, Lea Kiefer, et al.. (2022). Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 78(5). 1269–1279. 81 indexed citations

Donnelly, Helen K., Demissie Alemayehu, Barry I. Eisenstein, et al.. (2016). Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team. Clinical Infectious Diseases. 63(suppl 2). S39–S45. 4 indexed citations

Ellenberg, Susan S., et al.. (2016). Good Clinical Practice Training: Identifying Key Elements and Strategies for Increasing Training Efficiency. Therapeutic Innovation & Regulatory Science. 50(4). 480–486. 17 indexed citations

Ruopp, Marcus D., Karen Chiswell, Joshua T. Thaden, Kunal Merchant, & Ephraim L. Tsalik. (2015). Respiratory Tract Infection Clinical Trials from 2007 to 2012. A Systematic Review of ClinicalTrials.gov. Annals of the American Thoracic Society. 12(12). 1852–1863. 16 indexed citations

Lichtenstein, Gary R., Salam Zakko, Glenn L. Gordon, et al.. (2012). Mesalazine granules 1.5 g once‐daily maintain remission in patients with ulcerative colitis who switch from other 5‐ ASA formulations: a pooled analysis from two randomised controlled trials. Alimentary Pharmacology & Therapeutics. 36(2). 126–134. 8 indexed citations

Chang, Lin, William D. Chey, Douglas A. Drossman, et al.. (2012). Tu1403 Safety and Tolerability Profile of Rifaximin for Treatment of IBS Without Constipation: Results of a Pooled Analysis of Double-Blind, Placebo-Controlled Randomized Controlled Trials. Gastroenterology. 142(5). S–823. 3 indexed citations

Sanyal, A., K. Mullen, N M Bass, et al.. (2012). 645 RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT. Journal of Hepatology. 56. S255–S256. 6 indexed citations

Sanyal, A. K., N M Bass, Fred Poordad, et al.. (2010). 195 RIFAXIMIN DECREASES VENOUS AMMONIA CONCENTRATIONS AND TIME-WEIGHTED AVERAGE AMMONIA CONCENTRATIONS CORRELATE WITH OVERT HEPATIC ENCEPHALOPATHY (HE) AS ASSESSED BY CONN SCORE IN A 6-MONTH STUDY. Journal of Hepatology. 52. S84–S84. 7 indexed citations

10.

Lichtenstein, Gary R., Glenn L. Gordon, Salam Zakko, et al.. (2010). Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial. Alimentary Pharmacology & Therapeutics. 32(8). 990–999. 42 indexed citations

11.

Bass, Nathan M., Kevin D. Mullen, Arun J. Sanyal, et al.. (2010). Rifaximin Treatment in Hepatic Encephalopathy. New England Journal of Medicine. 362(12). 1071–1081. 848 indexed citations breakdown →

12.

Sanyal, A., N M Bass, Kathleen Mullen, et al.. (2010). 15 RIFAXIMIN TREATMENT IMPROVED QUALITY OF LIFE IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL. Journal of Hepatology. 52. S7–S7. 9 indexed citations

13.

Mullen, Kathleen, Samuel H. Sigal, Mahdi Sheikh, et al.. (2009). 207 SAFETY OF RIFAXIMIN IN PATIENTS WITH HEPATIC ENCEPHALOPATHY: RESULTS OF A RANDOMIZED, PHASE 3, PLACEBO-CONTROLLED CLINICAL TRIAL. Journal of Hepatology. 50. S84–S85. 4 indexed citations

14.

Knobil, Katharine, Kunal Merchant, Chris Kalberg, Amanda Emmett, & Michael J. Cicale. (2004). A Comparison of Patient Perceived Improvement in Symptoms After Initiating Therapy with Either Advair Diskus (fluticasone propionate/salmeterol) 250/50 or Ipratropium/Albuterol. CHEST Journal. 126(4). 806S–806S. 3 indexed citations

15.

Knobil, Katharine, Chris Kalberg, Kunal Merchant, Amanda Emmett, & Michael J. Cicale. (2004). Maintenance of Bronchodilator Response for Advair Diskus 250/50 (Fluticasone Propionate/Salmeterol) but not Ipratropium/Albuterol in Patients with COPD. CHEST Journal. 126(4). 807S–807S. 4 indexed citations

16.

Donohue, James F., Christopher Kalberg, Amanda Emmett, Kunal Merchant, & Katharine Knobil. (2004). A Short-Term Comparison of Fluticasone Propionate/Salmeterol with Ipratropium Bromide/Albuterol for the Treatment of COPD. PubMed. 3(3). 173–181. 39 indexed citations

17.

Merchant, Kunal, Raphael Nudelman, Wayne F. Beyer, et al.. (2002). OxyR. Cell. 109(3). 383–396. 383 indexed citations

18.

Marshall, Harvey E., Kunal Merchant, & Jonathan S. Stamler. (2000). Nitrosation and oxidation in the regulation of gene expression. The FASEB Journal. 14(13). 1889–1900. 350 indexed citations

19.

Merchant, Kunal, et al.. (1996). Deamination of Single-Stranded DNA Cytosine Residues in Aerobic Nitric Oxide Solution at Micromolar Total NO Exposures. Chemical Research in Toxicology. 9(5). 891–896. 25 indexed citations

20.

White, Franklin, David L. Balkwill, Duane A. Meeter, & Kunal Merchant. (1993). Further Studies on the Lysozyme-like Activity of α-Lactalbumin: Development of Alternative Methods of Assay. Analytical Biochemistry. 212(1). 263–268. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact